Lupin launches antidepressant in the US

Pharmaceutical major Lupin said that it launched a generic equivalent of Alvogen Group Holdings’ psychiatric drug Fluoxetine.

Fluoxetine tablets sold in 60 mg dose had annual sales of $41 million in the US market as of February 2019.

Fluoxetine is also sold under the brand name Prozac as a treatment for depression and other mental disorders.

Fluoxetine tablets are used in the treatment of Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD) in both adults and pediatrics. It is also used to treat Bulimia Nervosa, or eating disorder and panic disorder in adults.

Lupin received an approval from the US Food and Drug Administration for sales of tablets on February 12, 2019.

Mumbai-based Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.

It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.